LH — Labcorp Holdings Inc.

Labcorp Holdings Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $3.6 billion, up 9% year-over-year.
• Adjusted EPS: $4.18, a 19% increase from the previous year.
• Free Cash Flow: $281 million, compared to $162 million in Q3 2024.
• Diagnostics Revenue: $2.8 billion, an increase of 8.5% (6.3% organic growth).
• Biopharma Laboratory Services (BLS) Revenue: $799 million, up 8.3% (5.3% organic growth).
• Adjusted Operating Income: $513 million, or 14.4% of revenue, up from 13.4% the previous year.
• Debt: Total debt at $5.6 billion, with a leverage ratio of 2.4x gross debt to trailing 12-month adjusted EBITDA.

2. Strategic Updates and Business Highlights

• Continued momentum in Diagnostic Laboratories and Central Laboratory businesses.
• Successful integration of Invitae, contributing positively to revenue and margins.
• Expansion of partnerships and acquisitions, including agreements to acquire assets from Empire City Laboratories and Laboratory Alliance of Central New York.
• Introduction of innovative testing capabilities, including new oncology tests and consumer-driven testing options through Labcorp OnDemand.
• Launch of Labcorp Test Finder, a generative AI tool to improve test selection for providers.

3. Forward Guidance and Outlook

• 2025 Revenue Growth Guidance: Updated to 7.4% to 8%, with Diagnostics expected to grow 7.2% to 7.8% and BLS projected to grow 5.7% to 7.1%.
• Adjusted EPS Guidance: Expected range of $16.15 to $16.50, with a midpoint growth rate of 12%.
• Free Cash Flow Guidance: Projected between $1.165 billion and $1.285 billion.
• Anticipation of continued margin improvement across both Diagnostics and BLS segments.

4. Bad News, Challenges, or Points of Concern

• Early Development Revenue: Lower-than-expected growth leading to restructuring and divestiture of approximately $50 million in annual revenue.
• PAMA Legislation: Anticipated $100 million top-line impact in 2026 due to potential cuts, with ongoing advocacy efforts for legislative relief.
• Book-to-Bill Ratio: Q3 book-to-bill at 0.9, indicating potential future revenue challenges, particularly in Early Development.
• Market Conditions: Uncertainty around study start times affecting Early Development performance.

5. Notable Q&A Insights

• Utilization Trends: Management noted increased organic volume in Diagnostics, driven by demographic trends rather than concerns over ACA changes.
• Price/Mix Dynamics: Strong growth in organic price/mix attributed to increased tests per accession and Invitae's impact, although unit price remains flat.
• Central Lab Strength: Continued strong performance with expectations for mid-single-digit growth, offsetting Early Development weaknesses.
• Acquisition Strategy: Management remains open to lower-margin assets if they provide significant share gains in underpenetrated markets.
• Consumer Testing Growth: While consumer-driven testing is growing, it has not yet reached critical mass for separate reporting.

Overall, Labcorp demonstrated strong financial performance in Q3 2025, with strategic initiatives aimed at growth and innovation, despite facing challenges in specific segments and external regulatory pressures.